Special oil may tame seizures in rare brain energy disorder
NCT ID NCT02014883
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested triheptanoin oil in 20 people with GLUT1 deficiency syndrome, a rare genetic condition that prevents glucose from properly fueling the brain. The goal was to see if this special oil could reduce the number of seizures and abnormal movement episodes. Participants took the oil and were monitored for safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
triheptanoin oil
What this could lead to
If it works, this could provide a new treatment option to reduce seizures and abnormal movements in people with GLUT1 deficiency syndrome.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to all patients. There is also a risk of side effects like elevated propionylcarnitine levels, requiring dose adjustments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLUT1 DEFICIENCY SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brain and Spine Institute
Paris, 75013, France